Skip to main content
HRTX $0.27 +2.23%
HRTX logo
HRTX · Heron Therapeutics, Inc.
Track HRTX — free
$0.27 +0.01 (+2.23%) Play latest call Q2 2026 earnings call transcript
Market Cap
$50.25M
Shares
190.27M
Volume · Nov 19 3.61M Avg daily vol (3M) 4.54M
All webcasts

Earnings call · FY2026 Q3

Heron Therapeutics, Inc. (HRTX) Q3 2026 Earnings Call

Concluded Nov 9, 2026
Nov 9, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $35.25M -7.8% YoY
Diluted EPS -$0.03
Gross margin 74.6% +5.8 pp YoY
Net income -$5.01M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

8-K earnings release · filed Nov 9, 2026
Heron Therapeutics and CorMedix Therapeutics entered a definitive agreement for CorMedix to acquire substantially all of its assets, subject to stockholder approval and customary closing conditions. Q3 2026 net revenue was $35.3 million, versus $38.2 million in Q3 2025.
10-Q report · filed Nov 9, 2026
Heron Therapeutics agreed to sell substantially all assets to CorMedix for 14,583,333 shares and $145.0 million cash, plus royalties and earn-outs, with closing expected in the first quarter of 2027.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Quarter detail

How the reported period landed and where the business moved.

Revenue · products & services

CINVANTI$19.97M -16.6% YoY
ZYNRELEF$10.60M +13.8% YoY
Aponvie$4.53M +49.3% YoY
SUSTOL$152,000 -92% YoY
Full-screen source Call document